Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<ul>
<li>B&amp;K, a China-based clinical stage biotech company, launched its IPO to raise at USD 774 million via a Hong Kong listing.</li>
<li>In this note, we look at its fundamentals briefly, including its core products and its management team.</li>
<li>We deem the fundamentals of the deal weak and will avoid the deal.</li>
</ul>


B&amp;K, a China-based clinical stage biotech company, launched its IPO to raise at USD 774 million via a Hong Kong listing.
In this note, we look at its fundamentals briefly, including its core products and its management team.
We deem the fundamentals of the deal weak and will avoid the deal.


B&K (华芢生物科技) IPO: Weak Fundamentals

B&K Corporation

B&K (华芢生物科技) IPO: Weak Fundamentals